Author:
Farajzadeh-Dehkordi Mahvash,Samiee-Rad Fatemeh,Farzam Seyed Saeed,Javadi Amir,Cheraghi Sara,Hamedi-Asl Dariush,Rahmani Babak
Funder
Cellular and Molecular Research Center, Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,General Medicine
Reference40 articles.
1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the Vitamin K antagonists: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:204S-233S.
2. Kocael A, Eronat AP, Tüzüner MB, Ekmekçi A, Orhan AL, İkizceli İ, et al. Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey. Mol Biol Rep. 2019;46:1825–33.
3. Kim K-A, Song W-G, Lee H-M, Joo H-J, Park J-Y. Multiplex pyrosequencing method to determine CYP2C9* 3, VKORC1* 2, and CYP4F2* 3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups. Mol Biol Rep. 2014;41:7305–12.
4. Lee MTM, Klein TE. Pharmacogenetics of warfarin: challenges and opportunities. J Hum Genet. 2013;58:334–8.
5. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee M-TM, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood J Am Soc Hematol. 2010;115:3827–34.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献